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Abstract 
Purpose: To develop a predictive model and nomogram for maculopathy occurrence at 3 years after 106Ru/106Rh 
plaque brachytherapy in uveal melanoma. 
Material and methods: Clinical records of patients affected by choroidal melanoma and treated with 106Ru/106Rh 
plaque from December 2006 to December 2014 were retrospectively reviewed. Inclusion criteria were: dome-shaped 
melanoma, distance to the fovea > 1.5 mm, tumor thickness > 2 mm, and follow-up > 4 months. The delivered dose 
to the tumor apex was 100 Gy. Primary endpoint of this investigation was the occurrence of radiation maculopathy at 
3 years. Analyzed factors were as follows: gender, age, diabetes, tumor size (volume, area, largest basal diameter and 
apical height), type of plaque, distance to the fovea, presence of exudative detachment, drusen, orange pigment, radi-
ation dose to the fovea and sclera. Univariate and multivariate Cox proportional hazards analyses were used to define 
the impact of baseline patient factors on the occurrence of maculopathy. Kaplan-Meier curves were used to estimate 
freedom from the occurrence of the maculopathy. The model performance was evaluated through internal validation 
using area under the ROC curve (AUC), and calibration with Gronnesby and Borgan tests. 
Results: One hundred ninety-seven patients were considered for the final analysis. Radiation-related maculop-
athy at 3 years was observed in 41 patients. The proposed nomogram can predict maculopathy at 3 years with an 
AUC of 0.75. Distance to fovea appeared to be the main prognostic factor of the predictive model (hazard ratio of 
0.83 [0.76-0.90], p < 0.01). Diabetes (hazard radio of 2.92 [1.38-6.20], p < 0.01), and tumor volume (hazard radio of 21.6 
[1.66-281.14], p = 0.02) were significantly predictive for maculopathy occurrence. The calibration showed no statistical 
difference between actual and predicted maculopathy (p = 1). 
Conclusions: Our predictive model, together with its nomogram, could be a useful tool to predict the occurrence 
of radiation maculopathy at 3 years after the treatment. 
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Purpose 
Uveal melanoma is an uncommon cancer, affecting 
from 6 to 7 individuals per million per year [1]. The Collab-
orative Ocular Melanoma Study (COMS) proved plaque 
brachytherapy to be a reliable alternative to surgical enu-
cleation for the treatment of medium-sized choroidal mel-
anomas. The study demonstrated equivalent rates of local 
control and survival between plaque brachytherapy and 
enucleation [2,3,4,5,6,7,8,9,10]. Applicators loaded with 
125I have been used in the COMS study [2], and also for 
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this reason, the use of such applicators has become the pri-
mary choice for uveal melanoma brachytherapy in North 
America. 
Nevertheless, many European institutions have gained 
experience using 106Ru/106Rh, a beta emitter, mainly for the 
treatment of small and medium-sized choroidal melano-
mas, reporting comparable outcomes in terms of overall sur-
vival [11]. 106Ru/106Rh is a beta emitter with more restricted 
range in comparison to gamma sources, and offers some 
advantages with respect to 125I, such us a better radiation 
protection for the operators and less side effects for adjacent 
healthy tissues. Excellent local control outcomes have been 
reported by a number of groups using 106Ru/106Rh plaques 
for small-medium sized uveal melanoma with acceptable 
rates of radiation-induced complications [12,13,14]. Nase-
ripour et al. have also shown that 106Ru/106Rh brachythe-
rapy is a successful alternative to enucleation for thick 
uveal melanomas: lower doses of radiations to tumor apex, 
assured that enough dose is delivered to the sclera, can suc-
cessfully treat such tumors, probably as a consequence of 
the effects of radiation on tumor blood supply [15]. Further-
more, a dosimetric comparison of 125I versus 106Ru/106Rh 
plaques demonstrated that 106Ru/106Rh plaques can pro-
vide adequate dose coverage to small tumors, sparing 
critical nearby structures more effectively than 125I [16]. 
Dose distribution comparison between 125I and 106Ru/106Rh 
is reported in Figure 1. However, brachytherapy with 
106Ru/106Rh plaques is not free from local toxicity, and the 
benefits of saving the eye may be reduced by visual func-
tion impairment, secondary to radiation-induced toxicity 
(such as cataract, optic neuropathy or retinopathy) [17]. 
Radiation maculopathy appears to be the most com-
mon complication, although several effective therapy ap-
proaches for the prevention and treatment of this disease 
are available [18,19]. A radiation induced maculopathy 
predictive model could be a useful tool in order to identi-
fy the patients that could take more advantage from pre-
ventive strategies [20,21]. Primary aim of this study is to 
develop a nomogram for the prediction of such complica-
tion in patients affected by uveal melanoma who under-
went 106Ru/106Rh brachytherapy. 
Material and methods 
For this analysis, we considered all consecutive pa-
tients who underwent 106Ru/106Rh  plaque brachythera-
py for uveal melanoma at the Gemelli Advanced Radi-
ation Therapy Center from December 2006 to December 
2014. Clinical and therapy data were collected from the 
hospital multidivisional electronic database, and were 
electronically elaborated with the COBRA-Storage Sys-
tem (C-SS) to ensure patient’s privacy [22,23]. 
COBRA (Consortium for Brachytherapy Data Analy-
sis) provides a set of ontologies expressed in the Web On-
tology Language (OWL), and defined as “COBRA-ONT” 
to describe and share knowledge in an intelligent meet-
ing-room environment. 
COBRA-ONT has been used for the setup of our data-
base with an open architecture that forecasts future data 
integration with databases originating from other insti-
tutions, creating a shared-data environment to enlarge 
patients’ sample and better validate current results. 
Institutional review board and ethics committee ap-
proval for using data collecting software had been ob-
tained. Each patient was evaluated by a multidisciplinary 
tumor board, including ophthalmologists mainly in-
volved in ocular oncology, radiation oncologists, clinical 
oncologists, and medical physicists [24]. 
All patients underwent complete ophthalmic exam 
during the first visit and the successive follow-up con-
tacts. Slit lamp biomicroscopy, ophthalmoscopy with 
fundus photography, and A-B scan ultrasonography 
were routinely performed. Patient’s demographic charac-
teristics were collected, including age, gender, and medi-
Fig. 1. Comparison of dose distribution for 106Ru/106Rh (A) and 125I plaques (B). Dose normalized to apex of the tumor and 
expressed in percentage 
A B
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cal history. The presence of maculopathy was recorded at 
baseline and during each further follow-up visit, through 
a complete eye examination and optical coherence to-
mography (OCT). 
The considered tumor data included anatomical lo-
cation (choroidal, ciliary, cilio-choroidal, irido-ciliary, or 
irido-cilio-choroidal), location of tumor epicenter (supe-
rior, inferior, nasal, temporal, or posterior pole), tumor 
size (basal dimension and thickness evaluated with A-B 
scan ultrasonography), and tumor volume, calculated 
with treatment a planning system (TPS). 
Dosimetry for brachytherapy was performed using 
a dedicated 3D calculation software (Plaque SimulatorTM, 
Bebig, Berlin, Germany) [25]. 
The prescribed dose to the tumor apex was 100 Gy, 
and an extra safety margin of 1 mm was added to the 
diameters of tumor. Target geometry was discussed and 
validated in all cases together with ocular oncologists. 
Treatment approval criteria were 100 Gy dose delivered 
at tumor apex, with the entire volume receiving at least 
95% of the prescribed dose. Four types of 106Ru/106Rh 
plaques (Bebig, Germany) of different sizes (Mod-
els CCA, CCD, CCB, COB with nominal diameters of 
15.5 mm, 17.8 mm, 20 mm, and 20 mm, respectively) 
were available for treatment delivery. Patients inclusion 
criteria were: dome-shaped melanoma, distance to the fo-
vea > 1.5 mm, tumor thickness > 2 mm, and follow-up 
≥ 4 months. 
According to the INTERACTS (INTErventional Ra-
diotherapy ACtive Teaching School) guidelines for qual-
ity assurance in ocular melanoma brachytherapy, tumor 
localization is firstly performed using transillumination 
or indirect ophthalmoscopy. Tumor margins are then 
marked on the sclera with a surgical marking pen, and 
a dummy applicator is sutured in the appropriate posi-
tion. The loaded plaque will replace the dummy appli-
cator, and an ultrasound check will be postoperatively 
performed to verify the accuracy of plaque positioning. 
Follow-up examinations were planned fifteen days 
after surgery, then every four months for the first year; 
every six months for the following five years, and then 
annually. Ophthalmoscopy, slit lamp biomicroscopy, A-B 
scan ultrasonography, and fundus photography were re-
peated during each follow-up visit. 
A screening for secondarisms has been performed 
every six months with liver function tests and imaging 
(ultrasonography). The following covariates were con-
sidered for our analysis: gender, age, diabetes, tumor di-
mensional parameters (size, volume, area, largest basal 
diameter, and apical height), type of plaque, distance to 
the fovea, presence of exudative detachment, drusen or 
orange pigment presence, and radiation dose to fovea 
and sclera. 
Kaplan-Meier analysis with log-rank test [26] and uni-
variate Cox proportional hazards model at 3 years were 
performed to identify the covariates, which may have an 
effect on the outcome of maculopathy. Multivariate anal-
ysis was performed using Cox proportional hazard mod-
el and hazard ratios (HR) were calculated from the model 
coefficients for each covariate. A p-value ≤ 0.05 was con-
sidered significant. The stepwise Akaike’s information 
Table 1. Summary patient’s and tumor characte-




Quartile (first-third quartile) 57-74 
Gender 
Male 87 (44.15%) 
Female 110 (55.83%) 
Diabetes 
Yes 25 (12.69%) 
No 172 (87.30%) 
Hypertension 
Yes 94 (47.71%) 
No 103 (52.28%) 
Tumor staging* 
T1 87 (44.16%) 
T2 108 (54.82%) 
T3 2 (1.01%) 
Largest basal diameter (mm) 
Median 10.10
Quartile (first-third quartile) 8.41-11.87 
Tumor height (mm) 
Median 3.3 
Quartile (first-third quartile) 2.87-3.91
Total dose to disc (Gy) 
Median 17.72 
Quartile (first-third quartile) 1.63-49.26
Total dose to macula (Gy) 
Median 28.20 
Quartile (first-third quartile) 2.87-158
Total dose to sclera (Gy) 
Median 268.50 
Quartile (first-third quartile) 232.8-351.8
Volume (ml)
Median 0.19 
Quartile (first-third quartile) 0.13-0.28 
Distance to lens (mm) 
Median 17.26 
Quartile (first-third quartile) 14.79-18.45 
*AJCC seventh edition 
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one of them, re-treatment brachytherapy was required, 
while two patients underwent proton beam radiothera-
py. In total, 197 patients with a median age of 68 years 
(range, 17-92) were therefore considered for this analysis. 
The median age, age range, gender, medical history, and 
tumor staging [32], pathologic and dosimetric character-
istics are reported in Table 1. The median of the follow-up 
was 51 months (range, 4-107 months). 
Maculopathy at 3 years occurred in 41 patients (21%). 
The Kaplan-Meier curve is shown in Figure 2. 106Ru/106Rh 
plaques were used (Bebig, Germany) CCA in 66 cases, 
COB in 39 cases, CCB in 50 cases, and CCD in 42 cases. 
Fifty eight patients (29.7%) underwent transpupillary 
thermotherapy (TTT) as adjuvant therapy, mainly in case 
of juxtapapillary tumors. 
Thirteen patients (6.5%) died during follow-up period 
(4 deaths were attributed to metastatic uveal melanoma, 
Fig. 2. Kaplan-Meier curve of maculopathy (solid line) with 
confidence interval (dashed line) 
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criterion (AIC) selection method was applied to select the 
best final model [27], and discrimination power was eval-
uated using AUC of model (area under the curve) [28]. 
The time independence of predictors (Cox assumption) 
was verified using Schoenfeld residuals [29]. 
A linear cross-correlation matrix (Pearson’s χ2 test) 
was used to assess the presence of interactions among 
predictors: the statistical power of the model increases 
when no interactions among the predictors are observed. 
A calibration plot was also elaborated in order to estimate 
the accuracy of the model using Gronnesby and Borgan 
goodness-of-fit (GOF) test: p-values < 0.05 indicate lack of 
fit of the model. 
Finally, the entire dataset has been used for internal 
validation employing a resampling technique known as 
bootstrapping (TRIPOD type 1b internal validation [30]) 
in order to evaluate the performance of the developed 
model. In particular, 1,000 datasets with the same size of 
the primary patients dataset have been generated from 
the original one by random sampling with replacement. 
The AUC value has been then calculated for each 
dataset, and the final AUC represents their median value. 
A nomogram was then realized as tool to visualize the 
output of our predictive model. 
All statistical analyses have been performed using R 
version 3.3.1 [31]. 
Results 
Based on inclusion criteria, 202 patients were select-
ed from our database. A minimal plaque misplacement 
was observed in 5 cases during the follow-up visits, with 
the actinic scar showing to be not overlapping with the 
tumor borders. These cases were consequently excluded 
from our statistical analysis, as they had a pre-treatment 
plan different from the delivered one. 
All the patients with misplaced plaque required ad-
juvant transpupillary thermotherapy (TTT) and are cur-
rently alive with no evidence of distant metastases. For 
Table 2. Univariate and multivariate analysis for predicting the occurrence of maculopathy at 3 years 
Factors Univariate analysis Multivariate analysis
p-value Hazard ratio 95% CI p-value
Retinal detachment 0.01* – – 0.06
Diabetes 0.02* 2.92 1.38-6.20 < 0.01*
Tumor thickness (mm) 0.03* – – 0.53
Distance from fovea (mm) < 0.01* 0.83 0.76-0.90 < 0.01*
Dose to fovea (Gy) < 0.01* – – 0.80
Dose to optic disk (Gy) < 0.01* – – 0.65
Volume (ml) 0.03* 21.61 1.66-281.14 0.02*
Distance from optic nerve (mm) < 0.01* – – 0.15
Distance from lens (mm) < 0.01* – – 0.86
*Statistical significant: p-value < 0.05 
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while the remaining 9 deaths resulted to be unrelated to it). 
Thirteen patients (6.5%) had local failure: after evidence 
of disease recurrence, one patient required transcleral 
resection, two patients were re-treated with brachy-
therapy, eight patients underwent enucleation, one pa-
tient was treated with transpupillary thermotherapy, 
and two patients died due to metastatic disease. The sub-
set of univariate significant variables related to the devel-
Fig. 3. A) Receiver operating characteristic (ROC) curve of the multivariate Cox proportional hazard model based on dataset 
population. Area under the curve (AUC) is 0.75 (CI = 0.67-0.83). B) Internal validation: calibration plot estimating the observed 
probabilities of the outcome Maculopathy = TRUE (y-axis) in relation to the predicted probabilities (x-axis). Dotted line indi-
cates perfect prediction. Round black dots show subjects grouped by similar probabilities (quantiles) of dataset population, 
the brackets show 95% CI of the prediction, and the points are joint by straight lines. No statistically significant difference was 
observed between actual and predicted maculopathy (p = 1)
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Fig. 4. Nomogram using example 1: a woman with a tumor volume of 0.2 ml, tumor distance to fovea of 10 mm, and not affected 
by diabetes, would have 68 total points (13 + 55 + 0), corresponding to a 19% probability of developing maculopathy at 3 years 
after the treatment 
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opment of maculopathy is summarized in Table 2. Inter-
estingly, patients with primary lesion at a distance to the 
fovea > 15.45 mm did not develop maculopathy in our 
dataset. 
Plaque CCB, plaque CCD, plaque COB, age, gender, 
presence of orange pigment, largest basal diameter, scler-
al dose, presence of drusen, area of the tumor, and tumor 
thickness were not associated with a statistically signifi-
cant risk of developing radiation maculopathy. 
By multivariate analysis, a decrease in the distance 
to the fovea (hazard ratio of 0.83 [0.76-0.90], p < 0.01), 
an increase in tumor volume (hazard radio of 21.6 [1.66-
281.14], p = 0.02) and the presence of diabetes (hazard 
radio of 2.92 [1.38-6.20], p < 0.01) were found to be signif-
icant predictors of maculopathy (see Table 2). 
The proportional hazards assumption for Cox mod-
el was respected, and no linear interactions among the 
predictors were observed. An AUC model of 0.75 (CI = 
0.67-0.83) has been obtained (Figure 3A). 
Nomogram tool was used to graphically represent the 
final model, and could be used in order to predict the oc-
currence of maculopathy at 3 years after the brachyther-
apy treatment. No statistically significant difference 
(p = 1) has been observed between actual and predicted 
maculopathy, and the corresponding calibration plot, as 
shown in Figure 3B. 
The internal validation, using bootstrapping tech-
nique (1,000 random samples), confirmed the goodness 
of the model fit with an AUC of 0.75. 
Discussion 
A homogeneous group of patients affected by uveal 
melanoma was selected for this investigation. Radiation 
induced retinopathy/maculopathy and optic neuropathy 
represent late-onset complications of brachytherapy and 
are characterized by a slowly progressive occlusive vas-
culopathy, which produces variable ischemic damages 
and leads to subsequent visual loss [33]. To the best of our 
knowledge, some predictive models about visual acuity 
have been developed in recent years, but none predicting 
maculopathy in patients affected by uveal melanoma and 
treated with 106Ru/106Rh plaque is currently available 
[34,35]. 
The original contribute of this study is the realization 
of a nomogram for maculopathy occurrence at 3 years af-
ter treatment. 
Basing on patient and disease information generally 
available before treatment delivery, our model showed 
that the risk of maculopathy occurrence at 3 years can 
be best predicted by the following pool of covariates: re-
duced distance to the fovea [36], presence of diabetes, and 
Fig. 5. Nomogram using example 2: patient extracted from the database of the photodynamic therapy (PDT) experience. This 
patient had diabetes, a tumor thickness of 2.79 mm, tumor volume of 0.22 ml, and tumor distance to fovea of 3.83 mm before 
neoadjuvant PDT. After PDT, a reduction of tumor thickness (from 2.79 mm to 2.25 mm) and volume (from 0.22 ml to 0.12 ml) 
were observed. The nomogram shows a probability decrease to develop maculopathy from 86% to 74% in the patient in exam. 
Patient’s characteristics before PDT are indicated with solid line and after PDT with dashed line
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higher tumor volume. As an example, a woman without 
diabetes affected by a tumor with a volume of 0.2 ml and 
a distance to the fovea of 10 mm would have a probability 
of 19% to develop maculopathy at 3 years after the treat-
ment (Figure 4). 
The use of a decision support system (DSS) as the 
nomogram we propose, could be useful for determining 
patient’s visual prognosis, and lead to overall risk of visu-
al acuity loss reduction, allowing the best tailored treat-
ment choice for each patient both in neoadjuvant [37] or 
adjuvant treatment settings [38]. Furthermore, by giving 
patients more information regarding their prognosis, our 
nomogram could help to better assess and understand 
the risks associated with this radiation therapy procedure 
during the informed consent discussion. 
The performance of photodynamic therapy (PDT) as 
neoadjuvant treatment before brachytherapy for amela-
notic choroidal melanoma have been evaluated in a pre-
vious experience [37]. PDT appears to reduce tumor thick-
ness in 73.4% of cases with a mean reduction of 23.3%. 
Consequently, a dose reduction of 19.3% and 27.1% to 
fovea and optic nerve, respectively, can be appreciated. 
As a result, a significant decrease of irradiation side 
effects on visual function could be reached, without com-
promising disease control. Furthermore, our nomogram 
could be used to select patients affected by choroidal mel-
anoma, who could benefit more from neoadjuvant treat-
ments before brachytherapy, as tumor thickness appeared 
to be correlated with the disease volume (Figure 5). How-
ever, further studies are needed to better understand this 
correlation. 
In addition, patients with a high risk of maculopathy 
development might be candidates for trials evaluating 
both preventive approaches or the direct treatment of this 
condition [38]. 
Since only 21% of patients is expected to develop radi-
ation induced maculopathy, as demonstrated also in the 
present study, an accurate prediction model would help 
in identifying preventive treatments or support. 
The main limitation of this study is represented by the 
fact that our nomogram has not been externally validat-
ed using an independent dataset originating from other 
institutions. Therefore, an external validation of the pro-
posed model would be of great interest in order to con-
firm our observations on a more heterogeneous popula-
tion through a reliable generalization process. 
Conclusions 
The nomogram, based on our radiation induced mac-
ulopathy predictive model, appears to be a useful tool 
for maculopathy occurrence prediction at 3 years after 
brachytherapy for uveal melanomas. The use of such 
DSS could help clinicians to reliably identify patients 
with higher risk of visual loss, and plan the best treat-
ment for each of the patient on the basis of the character-
istics of both the tumor and the single patient. Moreover, 
the nomogram can be introduced in daily clinical prac-
tice to enrich and better describe the informed consent 
procedures, offering patients more reliable prognostic 
information. 
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